Efficiency and Tolerance of Rituximab (mabthéra) in Bullous Pemphigoid

Inclusion Criteria: * age \>= 18 and \< 80 * karnofsky \>= 50% * bullous pemphigoid clinical indication * cortico-dependent bullous pemphigoid in relapse for the second time * contraception used in female patient * consent obtained from patient Exclusion Criteria: * localized bullous pemphigoid in relapse (\<400cm2) * pemphigoid of pregnancy * dermatosis with IgA * pemphigoid with mucous damage * pregnant woman or nursing mother * woman able to have a baby and without contraception during the clinical trial period * age \< 18 or \> 80 * karnovsky \< 50% * significant disease or uncontrolled disease * serious antecedents of allergy or anaphylactic reaction with human monoclonal antibody * patient with depletion lymphocytic treatment or with initial rituximab treatment * unstable angina or ischemic heart disease * cardiac insufficiency * cardiac rhythm trouble uncontrolled * evolutive infection * immunodepression * neutrophil polynuclear in blood \< 1.5 G/l and /or platelet blood concentration \< 75G/l * positive HIV serology * positive hepatitis B and / or C serology * concomitant immunodepressor treatment able to induce depletion lymphocytic treatment * no consentment * antecedent of serious chronic or recurrent infection or other underlying pathology able to induce serious infection * antecedent of deep tissue infection occurred the previous year of inclusion